Quantum-Si Inc (QSI)
Health Care · Life sciences tools and proteomics · NASDAQ
Quantum-Si is pioneering next-generation single-molecule protein sequencing to democratize access to the proteome and unlock new biological insights.
What Quantum-Si Inc does
Quantum-Si is a life sciences company focused on proteomics, developing a proprietary, universal, single-molecule detection platform. Its technology enables next-generation protein sequencing (NGPS) to analyze proteins in a massively parallel fashion, aiming to provide faster and more affordable insights compared to traditional mass spectrometry-based methods. The company is currently transitioning from its Platinum instrument line to its next-generation Proteus platform, expected to launch in 2027.
Recent developments
The company updated its anticipated launch of the Proteus platform to Q2 2027 to include an additional design cycle. It also announced a 20% workforce reduction to align spending with the revised timeline and extended its expected cash runway into Q4 2028.
From Quantum-Si Inc's filing of 2026-08-13.
Themes: proteomics, next-generation protein sequencing (NGPS), single-molecule analysis, biomarker discovery, drug discovery, life sciences instrumentation
Fundamentals
- Price$1.16 as of 2026-10-20 close
- Market cap$254M as of 2026-08-11 (share count; price 2026-10-20)
- 1-year return-55.1% 2025-10-20 close $2.59 → 2026-10-20 close $1.16
- P/En/a negative earnings
- Net margin-4160.1% FY2025, SEC XBRL
- Gross margin+47.3% FY2025, SEC XBRL
- ROE-46.0% FY2025, SEC XBRL
- ROICn/a No figure: its pre-tax income was zero or negative, so there is no tax rate to apply.
- Debt / equityn/a No figure: its filing tags none of the debt lines we read, which is not evidence of zero debt.
- Revenue growth (YoY)-20.3% FY2025, SEC XBRL
- Beta2.41 as of 2026-09-02
- Last reported earnings2026-08-13 SEC EDGAR Form 8-K (Item 2.02)
How QSI compares in its sector
- net profit marginbottom 10% 430 covered Health Care peers, as of 2026-09-02
- operating marginbottom 10% 417 covered Health Care peers, as of 2026-09-02
- gross marginmiddle range 189 covered Health Care peers, as of 2026-09-02
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-02
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Quarterly results
| Quarter | Revenue | Gross profit | Operating income | Net income | Diluted EPS | Operating cash flow | Capex |
|---|---|---|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | $344000 | $172000 | -$26M | -$24M | -$0.11 | -$18M† | $78000† |
| Q1 FY2026 2026-03-31 | $258000 | $74000 | -$24M | -$22M | -$0.10 | -$26M | $279000 |
| Q4 FY2025 2025-12-31 | $451000† | $122000† | -$21M† | -$18M† | -$0.07† | -$16M† | -$17000† |
| Q3 FY2025 2025-09-30 | $552000 | $194000 | -$40M | -$36M | -$0.17 | -$32M† | $900000† |
| Q2 FY2025 2025-06-30 | $591000 | $351000 | -$30M | -$29M | -$0.16 | -$20M† | $327000† |
| Q1 FY2025 2025-03-31 | $842000 | $486000 | -$25M | -$19M | -$0.11 | -$26M | $1M |
| Q4 FY2024 2024-12-31 | $1M† | $610000† | -$31M† | -$33M† | -$0.23† | -$23M† | $1M† |
| Q3 FY2024 2024-09-30 | $787000 | $367000 | -$28M | -$25M | -$0.18 | -$23M† | $975000† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$24M
- Short-term investments$88M
- Total debtnot shown the filing tags none of the debt lines we read — not evidence of zero debt
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How Quantum-Si Inc looks technically
Quantum-Si Inc (QSI) is trading 20.9% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed below its 200-day average about 196 trading days ago — a "death cross", a bearish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 42, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 52, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 3 trading days ago (its momentum flipped negative). It made a new 20-day high about 13 trading days ago. It is 62.6% below its highest point of the past year.
Trend
9
| Distance from the 200-day | it is trading 20.9% above its 200-day average, the long-term trend line — a longer-term uptrend | +20.9% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $0.9323 | $0.9323 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $0.9592 | $0.9592 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 11 calendar days ago — the swings before that are what the structure reading is measured on | 11 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that upward direction; the labelling fails if price closes below 0.914. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a completed three-part correction. | possible upward five-wave sequence, in wave 4 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 196 trading days ago — a "death cross", a bearish long-term signal | 196 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 20.9% above | +20.9% |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 42, with buyers in control | 42.0 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 52, neither overbought (above 70) nor oversold (below 30) | 51.8 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($1.01 to $1.66) — its "stochastic" reading is 23 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 23.1 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 3 trading days ago (its momentum flipped negative) | 3 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $3.10 | $3.10 |
|---|---|---|
| From the 52-week high | it is 62.6% below its 52-week high (its highest price of the past year) | -62.6% |
| Above the 52-week low | it is 68.1% above its 52-week low (its lowest price of the past year) | +68.1% |
| Below the 52-week high | it is 62.6% below its highest point of the past year | 62.6% |
| Since a 20-day breakout | it made a new 20-day high about 13 trading days ago | 13 sessions |
| Since a 55-day breakout | it made a new 55-day high about 13 trading days ago | 13 sessions |
| All-time high | its highest closing price on record is $14.17 (set on 2021-07-12) | $14.17 |
| Given back of the 52-week move | over the past year its closes ranged ($0.702 to $2.63), and it has recovered roughly a quarter of its fall from last year’s high — 24% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $1.89 to $1.96. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 23.8% |
| From the all-time high | it is 91.8% below its all-time high | -91.8% |
| Nearest price level | it is trading 1.7% above a support level at $1.14 — a price it turned at twice since 2026-01-21, most recently on 2026-04-17. Since 2024-10-21 it has 9 such levels below the current price and 9 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -1.7% |
| All-time low | its lowest closing price on record is $0.6121 (set on 2024-11-19) | $0.6121 |
| Above the all-time low | it is 89.5% above its all-time low | +89.5% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 90% of the past ~6 months) | 90th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.1586 between its high and its low — about 13.7% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.1586 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $0.69 and $1.66 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $0.69 – $1.18 – $1.66 |
| Typical daily range (% of price) | its price moves about 13.7% in a typical session — among the most volatile in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 13.7% |
| Stretch from the 200-day average | it is trading 1.3 daily ranges above its 200-day average price (20.9% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.3 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.76× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 0.7% since the prior reading | +0.7% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a bullish engulfing | today it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | today |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-10-20 2.8% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -2.8% |
|---|---|---|
| Open gap | it gapped 3.6% below the previous close 6 sessions ago and has not traded back through the level it left behind at 1.53 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -3.6% |
| Gap filled | a 2.8% gap down opened on 2026-10-20 has been "filled" today — price traded back through the level the gap left behind, and it closed again during the very session that opened it | today |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 54.7 percentage points (the stock gained 55.7% while the market gained 1.0%) | +54.7% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 38.3 percentage points (the stock gained 42.0% while the market gained 3.6%) | +38.4% |
| vs market, 6 months | over the past 6 months this stock beat the market by 6.3 percentage points (the stock gained 14.9% while the market gained 8.5%) | +6.3% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 69.7 percentage points (the stock lost 55.1% while the market gained 14.6%) | -69.7% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: trading above its 200-day average, a strong uptrend, with buyers in control, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, MACD momentum is negative — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 36% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-14 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 5.4% of the share price. | +36.5% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 10% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $1.05 — a volume-weighted average of daily closes over 196 sessions, not a true tick-by-tick VWAP. | +10.4% |
|---|---|---|
| Vs the average paid since it last reported | the price is 2% below the average price paid since it last reported on 2026-08-13 (its 10-Q), so the typical buyer over that stretch is under water. That average is $1.18 — a volume-weighted average of daily closes over 48 sessions, not a true tick-by-tick VWAP. | -1.9% |
Price levels it has turned at before
QSI last closed at $1.16 on 2026-10-20. Since 2024-10-21 it has turned at 9 prices below its last close and 9 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $1.14 | Support | 1.7% below the last close | turned there twice · 2026-01-21 to 2026-04-17 |
| $1.18 | Resistance | 1.7% above the last close | turned there three times · 2024-12-19 to 2025-12-16 |
| $1.10 | Support | 5.2% below the last close | turned there twice · 2025-04-30 to 2026-03-10 |
| $1.07 | Support | 7.5% below the last close | turned there three times · 2025-04-21 to 2026-06-22 |
| $1.26 | Resistance | 8.6% above the last close | turned there twice · 2025-12-03 to 2026-06-02 |
| $1.33 | Resistance | 14.9% above the last close | turned there three times · 2025-12-24 to 2026-01-22 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes below $0.914.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $1.19 and $1.44 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a completed three-part correction, which fails on a close above $1.66.
This reading has stood for 16 trading days, since 2026-09-29.
Read from daily closes as of 2026-10-20.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Trading above the 50-day moving average · Tested and reclaimed 200-day support · Pulled back from the 12-month high · MACD just crossed bearish (12/26/9) · in a strong, established uptrend (ADX) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-20. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.67 mean, 1=Strong Buy…5=Strong Sell) — 3 analysts
- Mean price target$2.30 range $1.00 – $4.00; median $1.90
Analyst estimates, as of 2026-10-18. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for QSI
- Consensus EPS estimate-$0.12 next reporting period, as of 2026-10-18
- Estimate change, 30 days$0.00 from -$0.12, on 2026-09-13, 35-day window
- Readings revised upward0% of 9 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Significant history of operating losses and uncertainty regarding future profitability.","Reliance on the successful development and commercial launch of the Proteus platform to sustain and grow future revenue.","Risk of delisting from the Nasdaq Global Market if it fails to maintain the minimum $1.00 closing bid price requirement."]
What changed in the latest 10-Q
AI-assisted comparison of QSI's 10-Q filed 2026-05-07 against the prior one filed 2025-11-05.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing references Form 10-K for year ended December 31, 2025 filed March 3, 2026; older filing references Form 10-K for year ended December 31, 2024 filed March 3, 2025
- Newer filing covers three months ended March 31, 2026 and 2025; older filing covers three and nine months ended September 30, 2025 and 2024
- Newer filing adds: 'Our current platform includes our Platinum® NGPS line of instruments' (plural 'line' vs singular in older)
- Newer filing adds detailed financial table for three months ended March 31, 2026 vs 2025 showing product revenue decline from $808K to $216K
- Newer filing adds: 'In November 2025, we presented an updated technology and product roadmap'
- Newer filing adds: 'Proteus aims to provide single-molecule, amino acid level resolution while also providing anticipated significantly higher sequencing output per sample'
- Newer filing adds: 'The first generation of Proteus and associated sequencing consumables is anticipated to include motion control, liquid handling, and a new on-board single optical system'
- Newer filing adds: 'As a result of the anticipated launch of Proteus, we expect some customers may delay purchasing decisions for existing products, which is expected to adversely impact revenue until Proteus becomes commercially available'
- Newer filing adds comprehensive results of operations table with specific financial metrics and variance analysis
- Removed:
- Older filing includes 'Restructuring' section describing November 2024 organizational restructuring, 23% workforce reduction, and $2.3 million severance charges; not present in newer filing
- Older filing includes 'Equity Transactions' section with 'At-the-Market Equity Offering Program' describing September 26, 2025 Sales Agreement with Leerink Partners for $100 million offering; not present in newer filing (text cuts off)
- Older filing states 'Going forward, we intend to follow a systematic, phased approach to continue to successfully launch updates and enhancements to our platform'; removed in newer filing
- Older filing states Proteus 'is estimated to launch in the second half of 2026'; newer filing changes to 'anticipated to launch by the end of 2026'
- Older filing states 'Our evolving product roadmap provides for continued updates and enhancements'; newer filing replaces with 'In November 2025, we presented an updated technology and product roadmap'
- Reworded:
- Older: 'proprietary universal single-molecule detection platform'; Newer: 'proprietary, universal, single-molecule detection platform' (comma added)
- Older: 'Next-Gen Protein Sequencing™'; Newer: 'next-gen protein sequencing ("NGPS")' (formatting and capitalization change)
- Older: 'We believe that the ability'; Newer: 'We believe in the ability' (wording simplification)
- Older: 'Platinum NGPS instrument'; Newer: 'Platinum® NGPS line of instruments' (trademark and plural added)
- Older: 'Proteus is estimated to launch in the second half of 2026'; Newer: 'Proteus is anticipated to launch by the end of 2026' (timing language changed from 'second half' to 'by end')
- Older: 'Proteus aims to provide single molecule'; Newer: 'Proteus aims to provide single-molecule' (hyphenation added)
- Older: 'significantly higher sequencing output'; Newer: 'anticipated significantly higher sequencing output' (added 'anticipated')
- Notes:
- Newer filing text is truncated mid-sentence at 'Revenue, Cost of Revenue and Gross Profit' section; comparison limited to available text
- Older filing text is truncated at end of 'At-the-Market Equity Offering Program' section; full extent of removals cannot be verified
- Different fiscal periods compared (Q1 2026 vs Q3 2025) makes some structural differences expected
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 6 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-16. The 5 days since 2026-10-16 have not been checked yet.
- Last 30 days · read to 2026-10-160 buys · 3 sells ($12875) — 3 selling insiders
- Last 90 days · read to 2026-10-160 buys · 6 sells ($39411) — 3 selling insiders
- Last 180 days · read to 2026-10-160 buys · 14 sells ($110572) — 4 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-09-22. Based on Form 4 filings read through 2026-10-16; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about QSI's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
6 institutional 13F filers reported holding QSI as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 6
- Reported shares held 14,627,339
- Reported value $12,945,194
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about QSI's institutional holders → See what each manager we track holds →
Short interest (FINRA)
QSI had 11,830,534 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
Short interest as a percent of shares outstanding is not shown for QSI because we do not hold a verified share count to divide it by. The reported figures above are unaffected.
- Reported short interest (shares) 11,830,534
- Prior settlement (shares) 13,046,142
- Reported change -9.32%
- Days to cover (reported) 2.46
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Thermo Fisher Scientific (TMO)
- Bruker (BRKR)
- Agilent Technologies (A)
- Danaher (DHR)
- Waters (WAT)
- Illumina (ILMN)
- Pacific Biosciences (PACB)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare QSI vs…
Quantum-Si Inc is found in…
Frequently asked questions
What does Quantum-Si Inc (QSI) do?
Quantum-Si is a life sciences company focused on proteomics, developing a proprietary, universal, single-molecule detection platform. Its technology enables next-generation protein sequencing (NGPS) to analyze proteins in a massively parallel fashion, aiming to provide faster and more affordable insights compared to traditional mass spectrometry-based methods.
What sector is Quantum-Si Inc (QSI) in?
Quantum-Si Inc (QSI) is classified in the Health Care sector. Its industry is Life sciences tools and proteomics. It trades on NASDAQ.
Who are Quantum-Si Inc's (QSI) competitors?
Notable peers of Quantum-Si Inc (QSI) include Thermo Fisher Scientific, Bruker, Agilent Technologies, Danaher and Waters. This peer set is informational only — not financial advice.
Is Quantum-Si Inc (QSI) overbought or oversold right now?
Quantum-Si Inc (QSI) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 52, in the neutral middle (as of 2026-10-20). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on QSI come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.